EFFECT OF SELECTIVE COX-2 INHIBITOR (ETORICOXIB) ALONG WITH SCALING AND ROOT PLANING (SRP) ON CLINICAL PARAMETERS AND SALIVARY LEVEL OF SUPEROXIDE DISMUTASE IN CHRONIC GENERALIZED PERIODONTITIS A DOUBLE-BLIND, PLACEBO-CONTROLLED, DOUBLE-MASKED RANDOMIZED CONTROLLED TRIAL (RCT).
Overview
The hypothesis is that Etoricoxib act as an adjuvant to SRP in alleviating periodontal inflammation by: 1. improving clinical periodontal parameters and, 2. improving the salivary SOD levels.
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Primary Purpose: Treatment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Study Primary Completion Date: June 2013
Interventions
- Drug: Etoricoxib
Arms, Groups and Cohorts
- Experimental: Etoricoxib
- Etoricoxib 60 mg once daily
- Placebo Comparator: matching placebo
- matching placebo once daily
Clinical Trial Outcome Measures
Primary Measures
- change from baseline in salivary SOD level
- Time Frame: 3 months
Participating in This Clinical Trial
Inclusion Criteria
Forty patients with chronic generalized periodontitis - Exclusion Criteria:
with system illnesses, allergies, pregnancy, history of any drug intake and periodontal treatment in past 6 months.
Gender Eligibility: All
Minimum Age: 30 Years
Maximum Age: 60 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- Tatyasaheb Kore Dental College
- Provider of Information About this Clinical Study
- Principal Investigator: Dr. Sumit Sharad Shetgar, BDS (Post graduate student – Tatyasaheb Kore Dental College
- Overall Official(s)
- Dr.Sumit S. Shetgar, BDS, Principal Investigator, Tatyasaheb Kore Dental College And Research Centre
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.